This purpose-built AI is designed specifically for biotech & pharma, handling complex R&D tasks like clinical planning, protocol optimization, scenario modeling, and running 100+ experiments overnight with speed, security, and auditability that traditional methods can't match.
Key Highlights:
First commercial AI agent already shipping/deployed as part of the Researgency.ai rollout
Recent engagement with Red Light Holland to accelerate clinical development of Filament Health’s patented PEX010 botanical psilocybin candidate
Positions KALA as the emerging “Palantir for Biotech” with on-premises, secure AI infrastructure tailored for proprietary biological & clinical data
Targets massive efficiency gains across drug discovery, trials, regulatory, and commercial workflows for small-to-mid cap biotechs
With the agentic AI wave accelerating and $KALA trading around ~$0.18 (micro-cap ~$160M market cap, extreme volatility + high volume on AI headlines), this news reinforces their pivot into high-growth AI while leveraging biotech domain expertise.
Is $KALA delivering the real AI-biotech breakthrough or just hype in a crowded space? ???? What’s your price target — $1+, $5, or beyond if adoption takes off?
???? Full Story: https://finance.yahoo.com/sectors/healthcare/...00046.html